Chembio Diagnostics (CEMI) 10-Q7 Nov 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	8-May-13
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Chembio Diagnostics, Inc.	'
Entity Central Index Key	'0001092662	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	9,324,783
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $)	Sep. 30, 2013	Dec. 31, 2012
CURRENT ASSETS:	'	'
Cash and cash equivalents	$8,045,805	$2,951,859
Accounts receivable, net of allowance for doubtful accounts of $24,000 and $58,000 at March 31, 2013 and December 31, 2012, respectively	5,505,215	4,821,357
Inventories	3,747,181	2,488,071
Prepaid expenses and other current assets	708,615	747,463
TOTAL CURRENT ASSETS	18,006,816	11,008,750
FIXED ASSETS, net of accumulated depreciation	1,822,746	1,427,646
OTHER ASSETS:	'	'
Deferred tax asset, net of valuation allowance	3,874,148	4,233,194
License agreements, net of current portion	353,750	400,000
Deposits on manufacturing equipment	224,773	223,584
Deposits and other assets	44,176	41,976
TOTAL ASSETS	24,326,409	17,335,150
CURRENT LIABILITIES:	'	'
Accounts payable and accrued liabilities	3,935,036	3,303,923
Current portion of loans payable	0	51,236
Customer deposits	0	23,224
TOTAL CURRENT LIABILITIES	3,935,036	3,378,383
OTHER LIABILITIES:	'	'
Loans payable - net of current portion	0	82,247
TOTAL LIABILITIES	3,935,036	3,460,630
STOCKHOLDERS' EQUITY:	'	'
Preferred stock - 10,000,000 shares authorized, none outstanding	0	0
Common stock - $.01 par value; 100,000,000 shares authorized, 8,086,114 and 8,036,232 shares issued and outstanding for March 31, 2013 and December 31, 2012, respectively	93,248	80,362
Additional paid-in capital	46,827,310	41,116,149
Accumulated deficit	-26,529,185	-27,321,991
TOTAL STOCKHOLDERS' EQUITY	20,391,373	13,874,520
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$24,326,409	$17,335,150

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
CURRENT ASSETS:	'	'
Accounts receivable, allowance for doubtful accounts	$24,000	$58,000
STOCKHOLDERS' EQUITY:	'	'
Preferred stock - shares authorized (in shares)	10,000,000	10,000,000
Preferred stock - shares outstanding (in shares)	0	0
Common stock - par value (in dollars per share)	$0.01	$0.01
Common stock - shares authorized (in shares)	100,000,000	100,000,000
Common stock - shares issued (in shares)	9,324,783	8,036,232
Common stock - shares outstanding (in shares)	9,324,783	8,036,232

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
REVENUES:	'	'	'	'
Net product sales	$9,044,714	$4,745,094	$20,419,595	$16,919,436
R&D, milestone and grant revenue	572,027	262,292	1,268,821	825,093
License and Maintenance Revenue	898	0	898	0
TOTAL REVENUES	9,617,639	5,007,386	21,689,314	17,744,529
Cost of product sales	5,561,453	3,278,471	12,658,063	10,112,127
GROSS MARGIN	4,056,186	1,728,915	9,031,251	7,632,402
OPERATING EXPENSES:	'	'	'	'
Research and development expenses	1,602,297	1,005,645	4,148,201	3,363,819
Selling, general and administrative expenses	1,379,845	1,208,383	3,702,181	3,521,552
TOTAL OPERATING EXPENSES	2,982,142	2,214,028	7,850,382	6,885,371
INCOME FROM OPERATIONS	1,074,044	-485,113	1,180,869	747,031
OTHER INCOME (EXPENSES):	'	'	'	'
Gain (Loss) on Sale of fixed assets	0	0	7,500	0
Interest income	1,477	2,269	3,712	5,386
Interest expense	0	-2,815	-335	-7,573
TOTAL OTHER INCOME (EXPENSES)	1,477	-546	10,877	-2,187
INCOME BEFORE INCOME TAXES	1,075,521	-485,659	1,191,746	744,844
Income tax provision	358,850	-193,310	398,940	295,220
NET INCOME	$716,671	($292,349)	$792,806	$449,624
Basic earnings per share (in dollars per share)	$0.08	($0.04)	$0.09	$0.06
Diluted earnings per share (in dollars per share)	$0.07	($0.04)	$0.08	$0.05
Weighted average number of shares outstanding, basic (in shares)	9,324,783	8,001,472	8,886,998	7,974,447
Weighted average number of shares outstanding, diluted (in shares)	9,824,019	8,001,472	9,433,152	8,616,917

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Cash received from customers and grants	$21,005,456	$18,175,806
Cash paid to suppliers and employees	-20,425,025	-17,221,877
Interest received	3,712	5,386
Interest paid	-335	-7,573
Net cash provided by operating activities	583,808	951,742
Payments to Acquire Machinery and Equipment	-766,274	-715,195
Payments to Acquire Intangible Assets	-30,000	0
Net Cash Provided by (Used in) Investing Activities, Total	-796,274	-715,195
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from option and warrant exercises	31,433	98,815
Proceeds from Issuance of Common Stock	5,512,500	0
Expenses from sale of common stock	-104,038	0
Payment of loan obligation	-133,483	-41,175
Payment of capital lease obligation	0	-14,576
Net cash provided by (used in) financing activities	5,306,412	43,064
(DECREASE) IN CASH AND CASH EQUIVALENTS	5,093,946	279,611
Cash and cash equivalents - beginning of the period	2,951,859	3,010,954
Cash and cash equivalents - end of the period	8,045,805	3,290,565
RECONCILIATION OF NET INCOME TO NET CASH PROVIDED BY OPERATING ACTIVITIES:	'	'
Net Income	792,806	449,624
Adjustments:	'	'
Depreciation and amortization	446,235	404,570
Provision for deferred taxes	359,046	265,698
(Recovery of) Provision for doubtful accounts	-34,000	0
Share based compensation	284,152	241,067
Changes in assets and liabilities:	'	'
Accounts receivable	-649,858	431,277
Inventories	-1,259,110	-737,594
Prepaid expenses and other current assets	38,848	-23,957
Deposits and other assets	-2,200	497
Accounts payable and accrued liabilities	631,113	-102,664
Customer deposits and deferred revenue	-23,224	23,224
Net cash provided by operating activities	583,808	951,742
Supplemental disclosures for non-cash investing and financing activities:	'	'
Deposits on manufacturing equipment transferred to fixed assets	$296,788	$181,489

DESCRIPTION_OF_BUSINESS

DESCRIPTION OF BUSINESS	9 Months Ended
DESCRIPTION OF BUSINESS	Sep. 30, 2013
DESCRIPTION OF BUSINESS [Abstract]	'
DESCRIPTION OF BUSINESS	'
	NOTE 1 — DESCRIPTION OF BUSINESS:

	Chembio Diagnostics, Inc. (the "Company" or "Chembio") and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, and market rapid diagnostic tests that detect infectious diseases. The Company's main products are three rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, two of which were approved by the FDA in 2006; the third is sold for export only. Lateral Flow Rapid HIV tests represented 77 % of the Company's product revenues in the first nine months of 2013. The Company's products based on its patented Dual Path Platform (DPP®) platform represented approximately 21 % of the Company's product revenues in the first nine months of 2013. The Company also has other rapid tests that together represented approximately 2 % of sales in the first nine months of 2013. The Company's products are sold to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals and retail establishments both domestically and internationally. Chembio's products are sold under the Company's STAT PAK®, SURE CHECK® or DPP® registered trademarks, or under the private labels of its marketing partners. For example, the Clearview® label is owned by Alere, Inc. ("Alere"), which is the Company's exclusive marketing partner for its rapid HIV lateral flow test products in the United States. These products employ lateral flow technologies that are proprietary and/or licensed to the Company. All of the Company's products that are currently being developed are based on its patented DPP®, which is a unique diagnostic point-of-care platform that has certain advantages over lateral flow technology. In December 2012, the Company received FDA approval for its DPP® HIV 1/2 Assay for the detection of HIV antibodies in saliva, whole blood, serum and plasma samples.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

	a)	Basis of Presentation:
	The preceding (a) condensed consolidated balance sheet as of December 31, 2012, which has been derived from audited financial statements, and (b) the unaudited interim condensed consolidated financial statements as of September 30, 2013 and for the nine-month periods ended September 30, 2013 and 2012, respectively, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures, which are normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to provide for fair presentation. The interim financial information should be read in conjunction with the Financial Statements and the notes thereto, included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, previously filed with the SEC.

	On May 30, 2012, the Company effected a 1-for-8 reverse split of its common stock. This was done to allow the Company to move to the NASDAQ trading market from the QTCQB market, which occurred on June 7, 2012. As a result of the reverse stock split, the outstanding 63,967,263 common shares were reduced to 7,995,918 outstanding common shares on May 30, 2012. The effect of the reverse stock split has been retroactively reflected for all periods in these financial statements.

	In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the Company's condensed consolidated financial position as of September 30, 2013, its condensed consolidated results of operations for the three- and nine-month periods ended September 30, 2013 and 2012, respectively, and its condensed consolidated cash flows for the nine-month periods ended September 30, 2013 and 2012, as applicable, have been made. The interim results of operations are not necessarily indicative of the operating results for the full fiscal year or any future periods.


	CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
	NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	30-Sep-13
	(UNAUDITED)

		b)	Revenue Recognition
	The Company recognizes revenue for product sales in accordance with ASC 605, which provides that revenue is recognized when there is persuasive evidence of an arrangement, delivery has occurred or services have been rendered, the sales price is determinable, and collectability is reasonably assured. Revenue typically is recognized at time of shipment. Sales are recorded net of discounts, rebates and returns.

	For certain contracts, the Company recognizes revenue from non-milestone contracts and grant revenues when earned. Grants are invoiced after expenses are incurred. Revenues from projects or grants funded in advance are deferred until earned. As of September 30, 2013 and December 31, 2012, all advanced revenues were earned.

	The Company follows Financial Accounting Standards Board ("FASB") authoritative guidance ("guidance") prospectively for the recognition of revenue under the milestone method. The Company applies the milestone method of revenue recognition for certain collaborative research projects defining milestones at the inception of the agreement.

		c)	Inventories:
	Inventories consist of the following at:
			30-Sep-13				31-Dec-12
	Raw materials		$	1,945,929			$	1,418,071
	Work in process			879,806				561,530
	Finished goods			921,446				508,470
			$	3,747,181			$	2,488,071

		d)	Earnings Per Share:
	On May 30, 2012, the Company effected a 1-for-8 reverse split of its common stock. This was done to allow the Company to move to the NASDAQ trading market from the OTCQB market, which occurred on June 7, 2012. As a result of the stock split, the outstanding 63,967,263 common shares were reduced to 7,995,918 outstanding common shares on May 30, 2012. The effect of the reverse stock split has been retroactively reflected for all periods in these financial statements.

	Basic earnings per share is computed by dividing net income or loss by the weighted-average number of common shares outstanding for the period. Diluted income per share reflects the potential dilution from the exercise or conversion of other securities into common stock, but only if dilutive. The following securities, presented on a common share equivalent basis for the three and nine-month periods ended September 30, 2013 and 2012, have been included in the earnings per share computations:

		For the three months ended				For the nine months ended
		30-Sep-13		30-Sep-12		30-Sep-13		30-Sep-12
	Basic	9,324,783		8,001,472		8,886,998		7,974,447

	Diluted	9,824,019		8,001,472		9,433,152		8,616,917

	The following securities, presented on a common share equivalent basis for the three and nine-month periods ended September 30, 2013 and 2012, have been included in the diluted per share computations as the exercise prices of these securities were less than the stock price as of September 30, 2013 and 2012, respectively, or their inclusion would have been anti-dilutive as is the case with 617,680 options in the three months ended September 30, 2012, where the quarter showed a loss:

		For the three months ended					For the nine months ended
		30-Sep-13		30-Sep-12			30-Sep-13		30-Sep-12
	1999 and 2008 Plan Stock Options	499,236		-			546,154		642,470

	CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
	NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	30-Sep-13
	(UNAUDITED)

	The following securities, presented on a common share equivalent basis for the three and nine-month periods ended September 30, 2013 and 2012, have been excluded in the diluted per share computations as the exercise prices of these securities were greater than the stock price as of September 30, 2013 and 2012, respectively, except for 617,680 of the options reflected in the three months ended September 30, 2012 for which inclusion would have been dilutive due to the loss in the period:

		For the three months ended					For the nine months ended
		30-Sep-13		30-Sep-12			30-Sep-13		30-Sep-12
	1999 and 2008 Plan Stock Options	169,662		750,002			169,662		161,464


		e)	Employee Stock Option Plan:

	The Company had a 1999 Stock Option Plan ("SOP"). The total number of options available under the SOP was 375,000. As of September 30, 2013, there were 93,750 outstanding options under this SOP. No additional options may be issued under the SOP because it is more than 10 years after its adoption.

Effective June 3, 2008, the Company's stockholders voted to approve the 2008 Stock Incentive Plan ("SIP"), initially with 625,000 shares of Common Stock available to be issued. At the Annual Stockholder meeting on September 22, 2011, the Company's stockholders voted to approve an increase to the shares of Common Stock issuable under the SIP by 125,000 to 750,000. Under the terms of the SIP, the Compensation Committee of the Company's Board has the discretion to select the persons to whom awards are to be granted and the number of shares of common stock to be covered by each grant. Awards can be incentive stock options, restricted stock and/or restricted stock units. The awards become vested at such times and under such conditions as determined by the Compensation Committee. As of September 30, 2013, there were 144,220 options exercised, 562,648 options outstanding and 43,132 options or shares still available to be issued under the SIP.

The weighted average estimated fair value, at their respective dates of grant, of stock options granted in the three- and nine-month periods ended September 30, 2013 and 2012 was $5.39 and $3.26 per share, respectively. The fair value of options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon the historical volatility of our stock. The expected term is based on historical information.

The assumptions made in calculating the fair values of options granted during the periods indicated are as follows (no options issued in the three months ended September 30, 2013):

	For the three months ended				For the nine months ended
	30-Sep-13		30-Sep-12		30-Sep-13		30-Sep-12
Expected term (in years)	n/a		4		3		5-Apr
Expected volatility	n/a		99.60 % - 99.90 %		93.80 % - 101.30 %		99.60 % - 115.77 %
Expected dividend yield	n/a		0%		0%		0%
Risk-free interest rate	n/a		0.33 % - 0.37 %		0.34 % - 0.40 %		0.33 % - 0.37 %

The Company's results for the three-month periods ended September 30, 2013 and 2012 include share-based compensation expense totaling $62,000 and $59,000, respectively. Such amounts have been included in the Condensed Consolidated Statements of Operations within cost of goods sold ($14,000 and $10,000, respectively), research and development ($22,000 and $8,000, respectively) and selling, general and administrative expenses ($26,000 and $41,000, respectively). The results for the nine-month periods ended September 30, 2013 and 2012 include share-based compensation expense totaling $284,000 and $236,000, respectively. Such amounts have been included in the Condensed Consolidated Statements of Operations within cost of goods sold ($70,000 and $30,000, respectively), research and development ($84,000 and $65,000, respectively) and selling, general and administrative expenses ($130,000 and $141,000, respectively). The income tax benefit has been recognized in the statement of operations for share-based compensation arrangements.

Stock option compensation expense for the three and nine-month periods ended September 30, 2013 and 2012 is based on the estimated fair value, at the date of issuance, of options outstanding, which is being amortized on a straight-line basis over the requisite service period for each vesting portion of the award, except for those that vested immediately and for which the estimated fair value was expensed immediately.

CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
30-Sep-13
(UNAUDITED)

The following table provides stock option activity for the nine months ended September 30, 2013:

Stock Options		Number of Shares			Weighted Average Exercise Price per Share			Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at December 31, 2012			731,646		$	2.23		2.19 years		$	3,460,686

Granted			51,360			5.39
Exercised			(117,380	)		1.53
Forfeited/expired/cancelled			(9,228	)		3.99
Outstanding at September 30, 2013			656,398		$	2.57		1.90 years		$	705,000

Exercisable at September 30, 2013			504,022		$	2.04		1.41 years		$	807,500

As of September 30, 2013, there was $220,000 of net unrecognized compensation cost related to stock options that have not vested, which is expected to be recognized over a weighted average period of approximately 1.89 years. The total fair value of stock options vested during the nine-month periods ended September 30, 2013 and 2012 was approximately $39,000 and $245,000, respectively.

	f)	Geographic Information:
U.S. GAAP establishes standards for the manner in which business enterprises report information about operating segments in financial statements and requires that those enterprises report selected information. It also establishes standards for related disclosures about products and services, geographic areas, and major customers.

The Company produces only one group of similar products known collectively as "rapid medical tests". Management believes that it operates in a single business segment. Net product sales by geographic area are as follows:


		For the three months ended						For the nine months ended
		30-Sep-13			30-Sep-12			30-Sep-13			30-Sep-12
Africa		$	1,030,108		$	594,738		$	2,887,328		$	2,115,307
Asia			32,011			374,845			82,229			641,326
Europe			5,540			4,298			82,869			37,629
North America			2,199,090			1,235,074			7,484,668			6,501,210
South America			5,777,965			2,536,139			9,882,501			7,623,964
		$	9,044,714		$	4,745,094		$	20,419,595		$	16,919,436

CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
30-Sep-13
(UNAUDITED)

	g)	Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consist of:

		30-Sep-13				31-Dec-12
Accounts payable – suppliers		$	1,628,737			$	1,686,431
Accrued commissions			173,110				238,150
Accrued royalties / license fees			976,421				583,923
Accrued payroll			226,220				262,439
Accrued vacation			223,412				181,636
Accrued bonuses			422,225				155,663
Accrued expenses – other			284,911				195,681
TOTAL		$	3,935,036			$	3,303,923

COLLABORATIVE_RESEARCH_AND_DEV

COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS	9 Months Ended
	Sep. 30, 2013
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS [Abstract]	'
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS	'
	NOTE	3 — COLLABORATIVE RESEARCH AND DEVELOPMENT ARRANGEMENTS:

		a)	National Institutes of Health (NIH) Grant:
	In June 2009, the Company received a $2.8 million, three-year grant from the United States National Institutes of Health to complete development of a test for Leptospirosis. Grants are invoiced after expenses are incurred. The Company earned $- and $367,000 for the nine-month periods ended September 30, 2013 and 2012, respectively from this grant. The Company earned an aggregate of $2,800,000 from this grant from inception through September 30, 2013, of which $897,000 was paid to sub-contractors.

	In March 2011, the Company received a $2.9 million, three-year grant from the United States National Institutes of Health to complete development of a test for Tuberculosis. Grants are invoiced after expenses are incurred. The Company earned $470,000 and $487,000 for the nine-month periods ended September 30, 2013 and 2012, respectively from this grant. The Company earned $2,153,000 from this grant from inception through September 30, 2013 of which $651,000 was paid to sub-contractors.

		b)	Battelle/CDC DPP® Influenza Immunity Test:
	In July 2012, the Company entered into a follow-on, milestone-based development agreement of up to $480,000 based on Chembio's previous successful initial development of a multiplex rapid point-of-care ("POC") influenza immunity test utilizing its patented Dual Path Platform (DPP®) technology. The agreement was modified in April 2013, increasing the agreement to $953,000. The agreement contemplates a period of approximately nine months in which the follow-on development activity is to be completed. The Company earned $316,000 and 18,000 for the nine-month periods ended September 30, 2013 and 2012, respectively from this agreement. The Company earned $594,000 from this grant from inception through September 30, 2013.

		c)	Cooperative research agreement with a U.S. government agency:
	In May 2013, the Company was awarded a cooperative research agreement with a U.S. government agency for up to $753,000 for an eight month development project to develop rapid POC diagnostic tests for five infectious diseases associated with febrile illness. The Company earned $470,000 for the nine-month period ended September 30, 2013 from this agreement. The Company earned $470,000 from this grant from inception through September 30, 2013.

LOANS_PAYABLE

LOANS PAYABLE	9 Months Ended
LOANS PAYABLE	Sep. 30, 2013
LOANS PAYABLE	'
LOANS PAYABLE	'

	NOTE 4 — LOANS PAYABLE:
	On April 30, 2013, the Company entered into a new demand loan agreement ("Demand Note") with HSBC Bank, USA ("HSBC"). The Demand Note allows the Company to draw on the line from time to time an amount up to an aggregate of $2,000,000 outstanding at any one time. The accrued interest on the Demand Note is payable monthly at an interest rate equal to one-quarter percent above prime per annum. The Company can repay any or all of the principal balance outstanding at any time. This is a demand note for which the bank lender can demand repayment of the entire loan, with accrued interest, at any time. The loan is subject to annual reviews, as well as an annual 30-day clean-up, during which there can be no amounts outstanding.
	CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
	NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	30-Sep-13
	(UNAUDITED)

	The Security Agreement, related to the Demand Note, contains covenants that place restrictions on the Company's operations, including covenants relating to mergers, debt restrictions, capital expenditures, tangible net worth, net profit, leverage, fixed charge coverage, employee loan restrictions, distribution restrictions (common stock and preferred stock), dividend restrictions, restrictions on lease payments to affiliates, restrictions on changes in business, asset sale restrictions, restrictions on acquisitions and intercompany transactions, and restrictions on fundamental changes in the Company and in its business.

	The Company currently maintains its operating, payroll, and primary cash accounts at HSBC. As of September 30, 2013, nothing had been drawn down on the Demand Note.

RIGHTS_AGREEMENT

RIGHTS AGREEMENT	9 Months Ended
RIGHTS AGREEMENT	Sep. 30, 2013
RIGHTS AGREEMENT [Abstract]	'
RIGHTS AGREEMENT	'

	NOTE 5 — RIGHTS AGREEMENT:

	In March 2010, the Company entered into a Rights Agreement dated March 8, 2010 (the "Rights Agreement") between the Company and Action Stock Transfer Corp., as Rights Agent. Pursuant to the Rights Agreement, the Company declared a dividend distribution of one preferred share purchase right (a "Right") for each outstanding share of Common Stock, $0.01 par value (the "Common Stock"), of the Company. The Board of Directors set the payment date for the distribution of the Rights as March 8, 2010, and the Rights were distributed to the Company's shareholders of record on that date. The description and terms of the Rights are set forth in the Rights Agreement.

	Rights Initially Not Exercisable. The Rights are not exercisable until a Distribution Date, which is defined below. Until a Right is exercised, the holder thereof, in his capacity as a holder of Rights, will have no rights as a shareholder of the Company, including, without limitation, the right to vote or to receive dividends.

	Separation and Distribution of Rights. The Rights will be evidenced by the certificates for shares of Common Stock registered in the names of the holders thereof, and not by separate rights certificates until the earlier to occur of (i) the close of business on the tenth business day following a public announcement that an Acquiring Person (as defined in the Rights Agreement) acquired a Combined Ownership (as defined in the Rights Agreement) of 15 % or more of the outstanding shares of the Common Stock (the "Shares Acquisition Date") or (ii) the later of (A) the close of business on the tenth business day (or such later date as may be determined by action of the Board of Directors prior to such time as any person or group of affiliated or associated persons becomes an Acquiring Person) after the date that a tender or exchange offer or intention to commence a tender or exchange offer by any person is first published, announced, sent or given within the meaning of Rule 14d-4(A) under the Securities Exchange Act of 1934, as amended, the consummation of which would result in any person having Combined Ownership of 15 % or more of the outstanding shares of the Common Stock, or (B) if such a tender or exchange offer has been published, announced, sent or given before the date of the Rights Agreement, then the close of business on the tenth business day after the date the Rights Agreement was entered into (or such later date as may be determined by action of the Board of Directors prior to such time as any person becomes an Acquiring Person); (the earlier of such dates referred to in (i) and (ii), which date may include any such date that is after the date of the Rights Agreement but prior to the issuance of the Rights, being called the "Distribution Date").

COMMON_STOCK_WARRANTS_AND_OPTI

COMMON STOCK, WARRANTS AND OPTIONS	9 Months Ended
COMMON STOCK, WARRANTS AND OPTIONS	Sep. 30, 2013
COMMON STOCK, WARRANTS AND OPTIONS [Abstract]	'
COMMON STOCK, WARRANTS AND OPTIONS	'

	NOTE 6 — COMMON STOCK, WARRANTS AND OPTIONS:

	The Company entered into an employment agreement effective May 22, 2013 ("Employment Agreement"), with Ms. Klugewicz to serve as the Company's Chief Operating Officer, which included issuing incentive stock options to purchase 5,000 shares of the Company's common stock. Of these stock options, options to purchase 2,500 shares vest on each of the first two anniversaries of the effective date of the Employment Agreement. The exercise price for these options was to be equal to the last traded price for the Company's common stock on May 22, 2013, which was $4.50 per share. Each option granted will expire and terminate, if not exercised sooner, upon the earlier to occur of (a) 30 days after termination of the employee's employment with the Company or (b) the fifth anniversary of the effective date of the grant.

	CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
	NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	30-Sep-13
	(UNAUDITED)

	The Company closed on an underwritten public offering of 1,200,000 shares of its common stock at $5.00 per share on April 3, 2013. The net proceeds of the offering, after deducting the underwriters' discounts and other offering expenses payable by the Company, was approximately $5,401,000. The Company intends to use the net proceeds for business expansion and working capital.

	On February 26, 2013, the Company issued 16,360 options to purchase common stock to executives of the Company as part of their 2012 bonus. The options are exercisable immediately at $5.56 per share, which was the last traded price of the common stock on that day, and they expire five years from the date of issue.

	The Company entered into an employment agreement effective March 5, 2013 ("Employment Agreement"), with Mr. Esfandiari to continue as the Company's Senior Vice President of Research and Development, which included issuing incentive stock options to purchase 30,000 shares of the Company's common stock. Of these stock options, options to purchase 10,000 shares vest on each of the first three anniversaries of the effective date of the Employment Agreement. The exercise price for these options was to be equal to the last traded price for the Company's common stock on March 5, 2013, which was $5.44 per share. Each option granted will expire and terminate, if not exercised sooner, upon the earlier to occur of (a) 30 days after termination of the employee's employment with the Company or (b) the fifth anniversary of the effective date of the grant.

	As of September 30, 2013, the Company had no warrants outstanding to purchase shares of common stock.

COMMITMENTS_CONTINGENCIES_AND_

COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS	9 Months Ended
COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS	Sep. 30, 2013
COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS	'
COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS	'
	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

	a)	Basis of Presentation:
	The preceding (a) condensed consolidated balance sheet as of December 31, 2012, which has been derived from audited financial statements, and (b) the unaudited interim condensed consolidated financial statements as of September 30, 2013 and for the nine-month periods ended September 30, 2013 and 2012, respectively, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures, which are normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to provide for fair presentation. The interim financial information should be read in conjunction with the Financial Statements and the notes thereto, included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, previously filed with the SEC.

	On May 30, 2012, the Company effected a 1-for-8 reverse split of its common stock. This was done to allow the Company to move to the NASDAQ trading market from the QTCQB market, which occurred on June 7, 2012. As a result of the reverse stock split, the outstanding 63,967,263 common shares were reduced to 7,995,918 outstanding common shares on May 30, 2012. The effect of the reverse stock split has been retroactively reflected for all periods in these financial statements.

	In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the Company's condensed consolidated financial position as of September 30, 2013, its condensed consolidated results of operations for the three- and nine-month periods ended September 30, 2013 and 2012, respectively, and its condensed consolidated cash flows for the nine-month periods ended September 30, 2013 and 2012, as applicable, have been made. The interim results of operations are not necessarily indicative of the operating results for the full fiscal year or any future periods.


	CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
	NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	30-Sep-13
	(UNAUDITED)

		b)	Revenue Recognition
	The Company recognizes revenue for product sales in accordance with ASC 605, which provides that revenue is recognized when there is persuasive evidence of an arrangement, delivery has occurred or services have been rendered, the sales price is determinable, and collectability is reasonably assured. Revenue typically is recognized at time of shipment. Sales are recorded net of discounts, rebates and returns.

	For certain contracts, the Company recognizes revenue from non-milestone contracts and grant revenues when earned. Grants are invoiced after expenses are incurred. Revenues from projects or grants funded in advance are deferred until earned. As of September 30, 2013 and December 31, 2012, all advanced revenues were earned.

	The Company follows Financial Accounting Standards Board ("FASB") authoritative guidance ("guidance") prospectively for the recognition of revenue under the milestone method. The Company applies the milestone method of revenue recognition for certain collaborative research projects defining milestones at the inception of the agreement.

		c)	Inventories:
	Inventories consist of the following at:
			30-Sep-13				31-Dec-12
	Raw materials		$	1,945,929			$	1,418,071
	Work in process			879,806				561,530
	Finished goods			921,446				508,470
			$	3,747,181			$	2,488,071

		d)	Earnings Per Share:
	On May 30, 2012, the Company effected a 1-for-8 reverse split of its common stock. This was done to allow the Company to move to the NASDAQ trading market from the OTCQB market, which occurred on June 7, 2012. As a result of the stock split, the outstanding 63,967,263 common shares were reduced to 7,995,918 outstanding common shares on May 30, 2012. The effect of the reverse stock split has been retroactively reflected for all periods in these financial statements.

	Basic earnings per share is computed by dividing net income or loss by the weighted-average number of common shares outstanding for the period. Diluted income per share reflects the potential dilution from the exercise or conversion of other securities into common stock, but only if dilutive. The following securities, presented on a common share equivalent basis for the three and nine-month periods ended September 30, 2013 and 2012, have been included in the earnings per share computations:

		For the three months ended				For the nine months ended
		30-Sep-13		30-Sep-12		30-Sep-13		30-Sep-12
	Basic	9,324,783		8,001,472		8,886,998		7,974,447

	Diluted	9,824,019		8,001,472		9,433,152		8,616,917

	The following securities, presented on a common share equivalent basis for the three and nine-month periods ended September 30, 2013 and 2012, have been included in the diluted per share computations as the exercise prices of these securities were less than the stock price as of September 30, 2013 and 2012, respectively, or their inclusion would have been anti-dilutive as is the case with 617,680 options in the three months ended September 30, 2012, where the quarter showed a loss:

		For the three months ended					For the nine months ended
		30-Sep-13		30-Sep-12			30-Sep-13		30-Sep-12
	1999 and 2008 Plan Stock Options	499,236		-			546,154		642,470

	CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
	NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	30-Sep-13
	(UNAUDITED)

	The following securities, presented on a common share equivalent basis for the three and nine-month periods ended September 30, 2013 and 2012, have been excluded in the diluted per share computations as the exercise prices of these securities were greater than the stock price as of September 30, 2013 and 2012, respectively, except for 617,680 of the options reflected in the three months ended September 30, 2012 for which inclusion would have been dilutive due to the loss in the period:

		For the three months ended					For the nine months ended
		30-Sep-13		30-Sep-12			30-Sep-13		30-Sep-12
	1999 and 2008 Plan Stock Options	169,662		750,002			169,662		161,464


		e)	Employee Stock Option Plan:

	The Company had a 1999 Stock Option Plan ("SOP"). The total number of options available under the SOP was 375,000. As of September 30, 2013, there were 93,750 outstanding options under this SOP. No additional options may be issued under the SOP because it is more than 10 years after its adoption.

Effective June 3, 2008, the Company's stockholders voted to approve the 2008 Stock Incentive Plan ("SIP"), initially with 625,000 shares of Common Stock available to be issued. At the Annual Stockholder meeting on September 22, 2011, the Company's stockholders voted to approve an increase to the shares of Common Stock issuable under the SIP by 125,000 to 750,000. Under the terms of the SIP, the Compensation Committee of the Company's Board has the discretion to select the persons to whom awards are to be granted and the number of shares of common stock to be covered by each grant. Awards can be incentive stock options, restricted stock and/or restricted stock units. The awards become vested at such times and under such conditions as determined by the Compensation Committee. As of September 30, 2013, there were 144,220 options exercised, 562,648 options outstanding and 43,132 options or shares still available to be issued under the SIP.

The weighted average estimated fair value, at their respective dates of grant, of stock options granted in the three- and nine-month periods ended September 30, 2013 and 2012 was $5.39 and $3.26 per share, respectively. The fair value of options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon the historical volatility of our stock. The expected term is based on historical information.

The assumptions made in calculating the fair values of options granted during the periods indicated are as follows (no options issued in the three months ended September 30, 2013):

	For the three months ended				For the nine months ended
	30-Sep-13		30-Sep-12		30-Sep-13		30-Sep-12
Expected term (in years)	n/a		4		3		5-Apr
Expected volatility	n/a		99.60 % - 99.90 %		93.80 % - 101.30 %		99.60 % - 115.77 %
Expected dividend yield	n/a		0%		0%		0%
Risk-free interest rate	n/a		0.33 % - 0.37 %		0.34 % - 0.40 %		0.33 % - 0.37 %

The Company's results for the three-month periods ended September 30, 2013 and 2012 include share-based compensation expense totaling $62,000 and $59,000, respectively. Such amounts have been included in the Condensed Consolidated Statements of Operations within cost of goods sold ($14,000 and $10,000, respectively), research and development ($22,000 and $8,000, respectively) and selling, general and administrative expenses ($26,000 and $41,000, respectively). The results for the nine-month periods ended September 30, 2013 and 2012 include share-based compensation expense totaling $284,000 and $236,000, respectively. Such amounts have been included in the Condensed Consolidated Statements of Operations within cost of goods sold ($70,000 and $30,000, respectively), research and development ($84,000 and $65,000, respectively) and selling, general and administrative expenses ($130,000 and $141,000, respectively). The income tax benefit has been recognized in the statement of operations for share-based compensation arrangements.

Stock option compensation expense for the three and nine-month periods ended September 30, 2013 and 2012 is based on the estimated fair value, at the date of issuance, of options outstanding, which is being amortized on a straight-line basis over the requisite service period for each vesting portion of the award, except for those that vested immediately and for which the estimated fair value was expensed immediately.

CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
30-Sep-13
(UNAUDITED)

The following table provides stock option activity for the nine months ended September 30, 2013:

Stock Options		Number of Shares			Weighted Average Exercise Price per Share			Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at December 31, 2012			731,646		$	2.23		2.19 years		$	3,460,686

Granted			51,360			5.39
Exercised			(117,380	)		1.53
Forfeited/expired/cancelled			(9,228	)		3.99
Outstanding at September 30, 2013			656,398		$	2.57		1.90 years		$	705,000

Exercisable at September 30, 2013			504,022		$	2.04		1.41 years		$	807,500

As of September 30, 2013, there was $220,000 of net unrecognized compensation cost related to stock options that have not vested, which is expected to be recognized over a weighted average period of approximately 1.89 years. The total fair value of stock options vested during the nine-month periods ended September 30, 2013 and 2012 was approximately $39,000 and $245,000, respectively.

	f)	Geographic Information:
U.S. GAAP establishes standards for the manner in which business enterprises report information about operating segments in financial statements and requires that those enterprises report selected information. It also establishes standards for related disclosures about products and services, geographic areas, and major customers.

The Company produces only one group of similar products known collectively as "rapid medical tests". Management believes that it operates in a single business segment. Net product sales by geographic area are as follows:

CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
30-Sep-13
(UNAUDITED)

	g)	Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consist of:

		30-Sep-13				31-Dec-12
Accounts payable – suppliers		$	1,628,737			$	1,686,431
Accrued commissions			173,110				238,150
Accrued royalties / license fees			976,421				583,923
Accrued payroll			226,220				262,439
Accrued vacation			223,412				181,636
Accrued bonuses			422,225				155,663
Accrued expenses – other			284,911				195,681
TOTAL		$	3,935,036			$	3,303,923

NOTE 7 — COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS:

	a)	Economic Dependency:

The following table discloses product sales the Company had to each customer that purchased in excess of 10% of the Company's net product sales for the periods indicated:
	For the three months ended										For the nine months ended						Accounts Receivable as of
	30-Sep-13					30-Sep-12					30-Sep-13			30-Sep-12			30-Sep-13		30-Sep-12
	Sales			% of Sales		Sales			% of Sales		Sales		% of Sales	Sales		% of Sales
Customer 1	$	2,167,999		24		$	1,187,124		25		$	7,063,682	35	$	5,780,030	34	$	843,554	$	648,084
Customer 2		1,887,166		21			2,522,405		53			3,756,262	33		7,241,430	44		715,310		1,326,098
Customer 3		3,866,894		43			*		*			5,924,900	18		*	*		2,365,950		*
(*) Product sales did not exceed 10 % for the period indicated.

Note that sales include product sales only while accounts receivable reflects the total due from the customer, which includes freight.
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
30-Sep-13
(UNAUDITED)

The following table discloses purchases the Company made from each vendor that sold to the Company in excess of 10% of the Company's total purchases for the periods indicated:

	For the three months ended										For the nine months ended						Accounts Payable as of
	30-Sep-13					30-Sep-12					30-Sep-13			30-Sep-12			30-Sep-13		30-Sep-12
	Purchases			% of Purc.		Purchases			% of Purc.		Purchases		% of Purc.	Purchases		% of Purc.
Vendor 1	$	299,648		12		$	204,607		15		$	675,765	8	$	613,287	14	$	95,170	$	89,710
Vendor 2		275,539		11			211,020		16			840,923	10		589,224	13		57,555		60,073
(*) Purchases did not exceed 10% for the period indicated


The Company currently buys materials which are purchased under intellectual property rights agreements and are important components in its products. Management believes that other suppliers could provide similar materials on comparable terms. A change in suppliers, however, could cause a delay in manufacturing and a possible loss of sales, which could adversely affect operating results.

	b)	Governmental Regulation:
All of the Company's existing and proposed diagnostic products are regulated by the United States Food and Drug Administration, United States Department of Agriculture, certain U.S., state and local agencies, and/or comparable regulatory bodies in other countries. Most aspects of development, production, and marketing, including product testing, authorizations to market, labeling, promotion, manufacturing, and record keeping are subject to review. After marketing approval has been granted, Chembio must continue to comply with governmental regulations. Failure to comply with these regulations can result in significant penalties.

	c)	Employment Agreement:
The Company has employment contracts with three key employees. The contracts call for salaries presently aggregating $840,000 per year. The Klugewicz contract expires in May 2015, the Esfandiari contract expires in March 2016 and the Siebert employment contract expires in May 2014. In connection with the contract that expires in May 2015, the Company issued, in May 2013, 5,000 options to purchase common stock, with one-half vesting on each of the first and second anniversaries of the grant. In connection with the contract that expires in March 2016, the Company issued, in March 2013, 30,000 options to purchase common stock, with one-third vesting on each of the first, second and third anniversaries of the grant.

INCOME_TAXES

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2013
INCOME TAXES [Abstract]	'
INCOME TAXES	'

	NOTE 8 — INCOME TAXES:

	The Company's interim provision for income taxes is measured using an estimated annual effective tax rate of 35.1 % based on the 2012 statements. As per IRS rules, only 90 % of the taxable income can be offset by NOLs, and therefore 10 % of the tax rate equal to 3.5 %, or $39,800, was added to accrued expenses as an estimate of the amount to be owed, the full rate of 35.1 %, or $398,000, was expensed, and the balance of 31.6 %, or $358,200, reduced the carrying value of the deferred tax asset for the nine months ended September 30, 2013.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Basis of Presentation	'
	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

	a)	Basis of Presentation:
	The preceding (a) condensed consolidated balance sheet as of December 31, 2012, which has been derived from audited financial statements, and (b) the unaudited interim condensed consolidated financial statements as of September 30, 2013 and for the nine-month periods ended September 30, 2013 and 2012, respectively, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures, which are normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to provide for fair presentation. The interim financial information should be read in conjunction with the Financial Statements and the notes thereto, included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, previously filed with the SEC.

	On May 30, 2012, the Company effected a 1-for-8 reverse split of its common stock. This was done to allow the Company to move to the NASDAQ trading market from the QTCQB market, which occurred on June 7, 2012. As a result of the reverse stock split, the outstanding 63,967,263 common shares were reduced to 7,995,918 outstanding common shares on May 30, 2012. The effect of the reverse stock split has been retroactively reflected for all periods in these financial statements.

	In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the Company's condensed consolidated financial position as of September 30, 2013, its condensed consolidated results of operations for the three- and nine-month periods ended September 30, 2013 and 2012, respectively, and its condensed consolidated cash flows for the nine-month periods ended September 30, 2013 and 2012, as applicable, have been made. The interim results of operations are not necessarily indicative of the operating results for the full fiscal year or any future periods.
Revenue Recognition	'

	CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
	NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	30-Sep-13
	(UNAUDITED)

		b)	Revenue Recognition
	The Company recognizes revenue for product sales in accordance with ASC 605, which provides that revenue is recognized when there is persuasive evidence of an arrangement, delivery has occurred or services have been rendered, the sales price is determinable, and collectability is reasonably assured. Revenue typically is recognized at time of shipment. Sales are recorded net of discounts, rebates and returns.

	For certain contracts, the Company recognizes revenue from non-milestone contracts and grant revenues when earned. Grants are invoiced after expenses are incurred. Revenues from projects or grants funded in advance are deferred until earned. As of September 30, 2013 and December 31, 2012, all advanced revenues were earned.

	The Company follows Financial Accounting Standards Board ("FASB") authoritative guidance ("guidance") prospectively for the recognition of revenue under the milestone method. The Company applies the milestone method of revenue recognition for certain collaborative research projects defining milestones at the inception of the agreement.
Inventories	'
		c)	Inventories:
	Inventories consist of the following at:
			30-Sep-13				31-Dec-12
	Raw materials		$	1,945,929			$	1,418,071
	Work in process			879,806				561,530
	Finished goods			921,446				508,470
			$	3,747,181			$	2,488,071
Earnings Per Share	'
		d)	Earnings Per Share:
	On May 30, 2012, the Company effected a 1-for-8 reverse split of its common stock. This was done to allow the Company to move to the NASDAQ trading market from the OTCQB market, which occurred on June 7, 2012. As a result of the stock split, the outstanding 63,967,263 common shares were reduced to 7,995,918 outstanding common shares on May 30, 2012. The effect of the reverse stock split has been retroactively reflected for all periods in these financial statements.

	Basic earnings per share is computed by dividing net income or loss by the weighted-average number of common shares outstanding for the period. Diluted income per share reflects the potential dilution from the exercise or conversion of other securities into common stock, but only if dilutive. The following securities, presented on a common share equivalent basis for the three and nine-month periods ended September 30, 2013 and 2012, have been included in the earnings per share computations:

		For the three months ended				For the nine months ended
		30-Sep-13		30-Sep-12		30-Sep-13		30-Sep-12
	Basic	9,324,783		8,001,472		8,886,998		7,974,447

	Diluted	9,824,019		8,001,472		9,433,152		8,616,917

	The following securities, presented on a common share equivalent basis for the three and nine-month periods ended September 30, 2013 and 2012, have been included in the diluted per share computations as the exercise prices of these securities were less than the stock price as of September 30, 2013 and 2012, respectively, or their inclusion would have been anti-dilutive as is the case with 617,680 options in the three months ended September 30, 2012, where the quarter showed a loss:

		For the three months ended					For the nine months ended
		30-Sep-13		30-Sep-12			30-Sep-13		30-Sep-12
	1999 and 2008 Plan Stock Options	499,236		-			546,154		642,470

	CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
	NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	30-Sep-13
	(UNAUDITED)

	The following securities, presented on a common share equivalent basis for the three and nine-month periods ended September 30, 2013 and 2012, have been excluded in the diluted per share computations as the exercise prices of these securities were greater than the stock price as of September 30, 2013 and 2012, respectively, except for 617,680 of the options reflected in the three months ended September 30, 2012 for which inclusion would have been dilutive due to the loss in the period:

		For the three months ended					For the nine months ended
		30-Sep-13		30-Sep-12			30-Sep-13		30-Sep-12
	1999 and 2008 Plan Stock Options	169,662		750,002			169,662		161,464


Employee Stock Option Plan	'
		e)	Employee Stock Option Plan:

	The Company had a 1999 Stock Option Plan ("SOP"). The total number of options available under the SOP was 375,000. As of September 30, 2013, there were 93,750 outstanding options under this SOP. No additional options may be issued under the SOP because it is more than 10 years after its adoption.

	Effective June 3, 2008, the Company's stockholders voted to approve the 2008 Stock Incentive Plan ("SIP"), initially with 625,000 shares of Common Stock available to be issued. At the Annual Stockholder meeting on September 22, 2011, the Company's stockholders voted to approve an increase to the shares of Common Stock issuable under the SIP by 125,000 to 750,000. Under the terms of the SIP, the Compensation Committee of the Company's Board has the discretion to select the persons to whom awards are to be granted and the number of shares of common stock to be covered by each grant. Awards can be incentive stock options, restricted stock and/or restricted stock units. The awards become vested at such times and under such conditions as determined by the Compensation Committee. As of September 30, 2013, there were 144,220 options exercised, 562,648 options outstanding and 43,132 options or shares still available to be issued under the SIP.

	The weighted average estimated fair value, at their respective dates of grant, of stock options granted in the three- and nine-month periods ended September 30, 2013 and 2012 was $5.39 and $3.26 per share, respectively. The fair value of options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon the historical volatility of our stock. The expected term is based on historical information.

	The assumptions made in calculating the fair values of options granted during the periods indicated are as follows (no options issued in the three months ended September 30, 2013):

		For the three months ended				For the nine months ended
		30-Sep-13		30-Sep-12		30-Sep-13		30-Sep-12
	Expected term (in years)	n/a		4		3		5-Apr
	Expected volatility	n/a		99.60 % - 99.90 %		93.80 % - 101.30 %		99.60 % - 115.77 %
	Expected dividend yield	n/a		0%		0%		0%
	Risk-free interest rate	n/a		0.33 % - 0.37 %		0.34 % - 0.40 %		0.33 % - 0.37 %

	The Company's results for the three-month periods ended September 30, 2013 and 2012 include share-based compensation expense totaling $62,000 and $59,000, respectively. Such amounts have been included in the Condensed Consolidated Statements of Operations within cost of goods sold ($14,000 and $10,000, respectively), research and development ($22,000 and $8,000, respectively) and selling, general and administrative expenses ($26,000 and $41,000, respectively). The results for the nine-month periods ended September 30, 2013 and 2012 include share-based compensation expense totaling $284,000 and $236,000, respectively. Such amounts have been included in the Condensed Consolidated Statements of Operations within cost of goods sold ($70,000 and $30,000, respectively), research and development ($84,000 and $65,000, respectively) and selling, general and administrative expenses ($130,000 and $141,000, respectively). The income tax benefit has been recognized in the statement of operations for share-based compensation arrangements.

	Stock option compensation expense for the three and nine-month periods ended September 30, 2013 and 2012 is based on the estimated fair value, at the date of issuance, of options outstanding, which is being amortized on a straight-line basis over the requisite service period for each vesting portion of the award, except for those that vested immediately and for which the estimated fair value was expensed immediately.

	CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
	NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	30-Sep-13
	(UNAUDITED)

	The following table provides stock option activity for the nine months ended September 30, 2013:

	Stock Options		Number of Shares			Weighted Average Exercise Price per Share			Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
	Outstanding at December 31, 2012			731,646		$	2.23		2.19 years		$	3,460,686

	Granted			51,360			5.39
	Exercised			(117,380	)		1.53
	Forfeited/expired/cancelled			(9,228	)		3.99
	Outstanding at September 30, 2013			656,398		$	2.57		1.90 years		$	705,000

	Exercisable at September 30, 2013			504,022		$	2.04		1.41 years		$	807,500

	As of September 30, 2013, there was $220,000 of net unrecognized compensation cost related to stock options that have not vested, which is expected to be recognized over a weighted average period of approximately 1.89 years. The total fair value of stock options vested during the nine-month periods ended September 30, 2013 and 2012 was approximately $39,000 and $245,000, respectively.
Geographic Information	'

		f)	Geographic Information:
	U.S. GAAP establishes standards for the manner in which business enterprises report information about operating segments in financial statements and requires that those enterprises report selected information. It also establishes standards for related disclosures about products and services, geographic areas, and major customers.

	The Company produces only one group of similar products known collectively as "rapid medical tests". Management believes that it operates in a single business segment. Net product sales by geographic area are as follows:


			For the three months ended						For the nine months ended
			30-Sep-13			30-Sep-12			30-Sep-13			30-Sep-12
	Africa		$	1,030,108		$	594,738		$	2,887,328		$	2,115,307
	Asia			32,011			374,845			82,229			641,326
	Europe			5,540			4,298			82,869			37,629
	North America			2,199,090			1,235,074			7,484,668			6,501,210
	South America			5,777,965			2,536,139			9,882,501			7,623,964
			$	9,044,714		$	4,745,094		$	20,419,595		$	16,919,436
Accounts Payable and Accrued Liabilities	'
	CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
	NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	30-Sep-13
	(UNAUDITED)

		g)	Accounts Payable and Accrued Liabilities
	Accounts payable and accrued liabilities consist of:

			30-Sep-13				31-Dec-12
	Accounts payable – suppliers		$	1,628,737			$	1,686,431
	Accrued commissions			173,110				238,150
	Accrued royalties / license fees			976,421				583,923
	Accrued payroll			226,220				262,439
	Accrued vacation			223,412				181,636
	Accrued bonuses			422,225				155,663
	Accrued expenses – other			284,911				195,681
	TOTAL		$	3,935,036			$	3,303,923

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	Sep. 30, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Schedule of inventories	'
	Inventories consist of the following at:
			30-Sep-13				31-Dec-12
	Raw materials		$	1,945,929			$	1,418,071
	Work in process			879,806				561,530
	Finished goods			921,446				508,470
			$	3,747,181			$	2,488,071
Schedule of weighted average shares used for computation of basic and diluted earnings per share	'
	Basic earnings per share is computed by dividing net income or loss by the weighted-average number of common shares outstanding for the period. Diluted income per share reflects the potential dilution from the exercise or conversion of other securities into common stock, but only if dilutive. The following securities, presented on a common share equivalent basis for the three and nine-month periods ended September 30, 2013 and 2012, have been included in the earnings per share computations:

		For the three months ended				For the nine months ended
		30-Sep-13		30-Sep-12		30-Sep-13		30-Sep-12
	Basic	9,324,783		8,001,472		8,886,998		7,974,447

	Diluted	9,824,019		8,001,472		9,433,152		8,616,917
Schedule of common share equivalent basis, used in diluted per share computations	'
	The following securities, presented on a common share equivalent basis for the three and nine-month periods ended September 30, 2013 and 2012, have been included in the diluted per share computations as the exercise prices of these securities were less than the stock price as of September 30, 2013 and 2012, respectively, or their inclusion would have been anti-dilutive as is the case with 617,680 options in the three months ended September 30, 2012, where the quarter showed a loss:

		For the three months ended					For the nine months ended
		30-Sep-13		30-Sep-12			30-Sep-13		30-Sep-12
	1999 and 2008 Plan Stock Options	499,236		-			546,154		642,470
Assumptions made in calculating fair values of options	'

	The assumptions made in calculating the fair values of options granted during the periods indicated are as follows (no options issued in the three months ended September 30, 2013):

		For the three months ended				For the nine months ended
		30-Sep-13		30-Sep-12		30-Sep-13		30-Sep-12
	Expected term (in years)	n/a		4		3		5-Apr
	Expected volatility	n/a		99.60 % - 99.90 %		93.80 % - 101.30 %		99.60 % - 115.77 %
	Expected dividend yield	n/a		0%		0%		0%
	Risk-free interest rate	n/a		0.33 % - 0.37 %		0.34 % - 0.40 %		0.33 % - 0.37 %
Stock option activity	'

	The assumptions made in calculating the fair values of options granted during the periods indicated are as follows (no options issued in the three months ended September 30, 2013):

		For the three months ended				For the nine months ended
		30-Sep-13		30-Sep-12		30-Sep-13		30-Sep-12
	Expected term (in years)	n/a		4		3		5-Apr
	Expected volatility	n/a		99.60 % - 99.90 %		93.80 % - 101.30 %		99.60 % - 115.77 %
	Expected dividend yield	n/a		0%		0%		0%
	Risk-free interest rate	n/a		0.33 % - 0.37 %		0.34 % - 0.40 %		0.33 % - 0.37 %


	CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
	NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	30-Sep-13
	(UNAUDITED)

	The following table provides stock option activity for the nine months ended September 30, 2013:

	Stock Options		Number of Shares			Weighted Average Exercise Price per Share			Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
	Outstanding at December 31, 2012			731,646		$	2.23		2.19 years		$	3,460,686

	Granted			51,360			5.39
	Exercised			(117,380	)		1.53
	Forfeited/expired/cancelled			(9,228	)		3.99
	Outstanding at September 30, 2013			656,398		$	2.57		1.90 years		$	705,000

	Exercisable at September 30, 2013			504,022		$	2.04		1.41 years		$	807,500
Net product sales by geographic area	'

			For the three months ended						For the nine months ended
			30-Sep-13			30-Sep-12			30-Sep-13			30-Sep-12
	Africa		$	1,030,108		$	594,738		$	2,887,328		$	2,115,307
	Asia			32,011			374,845			82,229			641,326
	Europe			5,540			4,298			82,869			37,629
	North America			2,199,090			1,235,074			7,484,668			6,501,210
	South America			5,777,965			2,536,139			9,882,501			7,623,964
			$	9,044,714		$	4,745,094		$	20,419,595		$	16,919,436
Schedule of accounts payable and accrued liabilities	'
	Accounts payable and accrued liabilities consist of:

			30-Sep-13				31-Dec-12
	Accounts payable – suppliers		$	1,628,737			$	1,686,431
	Accrued commissions			173,110				238,150
	Accrued royalties / license fees			976,421				583,923
	Accrued payroll			226,220				262,439
	Accrued vacation			223,412				181,636
	Accrued bonuses			422,225				155,663
	Accrued expenses – other			284,911				195,681
	TOTAL		$	3,935,036			$	3,303,923

COMMITMENTS_CONTINGENCIES_AND_1

COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Tables)	9 Months Ended
COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Tables)	Sep. 30, 2013
COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS	'
Customer and purchase concentration risks	'
	NOTE 7 — COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS:

		a)	Economic Dependency:

	The following table discloses product sales the Company had to each customer that purchased in excess of 10% of the Company's net product sales for the periods indicated:
		For the three months ended						For the nine months ended						Accounts Receivable as of
		30-Sep-13			30-Sep-12			30-Sep-13			30-Sep-12			30-Sep-13		30-Sep-12
		Sales		% of Sales	Sales		% of Sales	Sales		% of Sales	Sales		% of Sales
	Customer 1	$	2,167,999	24	$	1,187,124	25	$	7,063,682	35	$	5,780,030	34	$	843,554	$	648,084
	Customer 2		1,887,166	21		2,522,405	53		3,756,262	33		7,241,430	44		715,310		1,326,098
	Customer 3		3,866,894	43		*	*		5,924,900	18		*	*		2,365,950		*
	(*) Product sales did not exceed 10 % for the period indicated.

	Note that sales include product sales only while accounts receivable reflects the total due from the customer, which includes freight.
	CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARY
	NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	30-Sep-13
	(UNAUDITED)

	The following table discloses purchases the Company made from each vendor that sold to the Company in excess of 10% of the Company's total purchases for the periods indicated:

		For the three months ended						For the nine months ended						Accounts Payable as of
		30-Sep-13			30-Sep-12			30-Sep-13			30-Sep-12			30-Sep-13		30-Sep-12
		Purchases		% of Purc.	Purchases		% of Purc.	Purchases		% of Purc.	Purchases		% of Purc.
	Vendor 1	$	299,648	12	$	204,607	15	$	675,765	8	$	613,287	14	$	95,170	$	89,710
	Vendor 2		275,539	11		211,020	16		840,923	10		589,224	13		57,555		60,073
	(*) Purchases did not exceed 10% for the period indicated


	The Company currently buys materials which are purchased under intellectual property rights agreements and are important components in its products. Management believes that other suppliers could provide similar materials on comparable terms. A change in suppliers, however, could cause a delay in manufacturing and a possible loss of sales, which could adversely affect operating results.

		b)	Governmental Regulation:
	All of the Company's existing and proposed diagnostic products are regulated by the United States Food and Drug Administration, United States Department of Agriculture, certain U.S., state and local agencies, and/or comparable regulatory bodies in other countries. Most aspects of development, production, and marketing, including product testing, authorizations to market, labeling, promotion, manufacturing, and record keeping are subject to review. After marketing approval has been granted, Chembio must continue to comply with governmental regulations. Failure to comply with these regulations can result in significant penalties.

		c)	Employment Agreement:
	The Company has employment contracts with three key employees. The contracts call for salaries presently aggregating $840,000 per year. The Klugewicz contract expires in May 2015, the Esfandiari contract expires in March 2016 and the Siebert employment contract expires in May 2014. In connection with the contract that expires in May 2015, the Company issued, in May 2013, 5,000 options to purchase common stock, with one-half vesting on each of the first and second anniversaries of the grant. In connection with the contract that expires in March 2016, the Company issued, in March 2013, 30,000 options to purchase common stock, with one-third vesting on each of the first, second and third anniversaries of the grant.

DESCRIPTION_OF_BUSINESS_Detail

DESCRIPTION OF BUSINESS (Details)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
DESCRIPTION OF BUSINESS (Details)	Lateral Flow Rapid HIV Tests [Member]	Products Based on Patented DPP Platform [Member]	Other Rapid Tests [Member]
Product Information [Line Items]	'	'	'
Percentage of net product revenue to total net revenue (in hundredths)	77.00%	21.00%	2.00%

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

22-May-13

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

30-May-12

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2008

Africa [Member]

Asia [Member]

Europe [Member]

North America [Member]

South America [Member]

Cost of Goods Sold [Member]

Research and Development Expense [Member]

Selling, General and Administrative Expenses [Member]

Minimum [Member]

Maximum [Member]

Stock Options [Member]

1999 Stock Option Plan [Member]

2008 Stock Incentive Plan [Member]

Minimum [Member]

Stock Options [Member]

Basis of Presentation [Abstract]

Reverse stock split conversion ratio

'1-for-8

Common stock outstanding before reverse stock split (in shares)

63,967,263

Common stock outstanding after reverse stock split (in shares)

7,995,918

Inventories [Abstract]

Raw materials

$1,945,929

$1,418,071

Work in process

879,806

561,530

Finished goods

921,446

508,470

Inventories

3,747,181

2,488,071

Earnings (Loss) Per Share [Abstract]

Reverse stock split conversion ratio

'1-for-8

Common stock outstanding before reverse stock split (in shares)

63,967,263

Common stock outstanding after reverse stock split (in shares)

7,995,918

Summary of weighted average shares used for computation of basic and diluted earnings per share [Abstract]

Basic (in shares)

9,324,783

8,001,472

8,886,998

7,974,447

Diluted (in shares)

9,824,019

8,001,472

9,433,152

8,616,917

Summary of common share equivalent basis, used in diluted per share computations [Abstract]

1999 and 2008 Plan Stock Options (in shares)

499,236

546,154

642,470

Options and warrants excluded from calculation of diluted per common share equivalent because the effect would have been anti-dilutive (in shares)

169,662

750,002

169,662

161,464

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares authorized under the plan (in shares)

375,000

750,000

625,000

Number of stock options outstanding under the plan (in shares)

656,398

731,646

93,750

562,648

Maximum period of stock option issuance after adoption of SOP

'10 years

Increase in number of shares authorized (in shares)

125,000

Number of stock options exercised under the plan (in shares)

117,380

144,220

Options or shares still available to be issued (in shares)

43,132

Weighted average estimated grant-date fair value of stock options granted (in dollars per share)

$4.78

$5.39

$3.26

Assumptions made in calculating fair values of options [Abstract]

Expected term

'3 years

'4 years

'5 years

'4 years

Expected volatility (in hundredths)

93.80%

99.60%

99.90%

101.30%

115.77%

99.60%

Expected dividend yield (in hundredths)

0.00%

Risk-free interest rate (in hundredths)

0.34%

0.33%

0.37%

0.40%

0.37%

0.33%

Stock options, number of shares [Roll forward]

Granted (in shares)

5,000

30,000

51,360

Exercised (in shares)

-117,380

-144,220

Forfeited/expired/cancelled (in shares)

-9,228

Outstanding, end of period (in shares)

656,398

731,646

93,750

562,648

Exercisable, end of period (in shares)

504,022

Stock options, outstanding, weighted average exercise price per share [Roll Forward]

Granted (in dollars per share)

$4.50

$5.39

Exercised (in dollars per share)

$1.53

Forfeited/expired/cancelled (in dollars per share)

$3.99

Outstanding, end of period (in dollars per share)

$2.57

$2.23

Exercisable, end of period (in dollars per share)

$2.04

Stock options, additional disclosure [Abstract]

Outstanding, weighted average remaining contractual term, beginning of period

'1 year 10 months 24 days

'2 years 2 months 8 days

Outstanding, weighted average remaining contractual term, end of period

'1 year 10 months 24 days

'2 years 2 months 8 days

Exercisable, weighted average remaining contractual term, end of period

'1 year 4 months 28 days

Outstanding, aggregate intrinsic value, end of period

705,000

3,460,686

Exercisable, aggregate intrinsic value, end of period

807,500

Net unrecognized compensation cost

220,000

Weighted average period for recognition of net unrecognized compensation cost (in years)

'1 year 10 months 20 days

Total fair value of stock options vested during period

39,000

245,000

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Allocated share-based compensation expense

62,000

59,000

284,000

236,000

14,000

10,000

70,000

30,000

22,000

8,000

84,000

65,000

26,000

41,000

130,000

141,000

Revenues from External Customers [Line Items]

Number of product groups

Net product sales

9,044,714

4,745,094

20,419,595

16,919,436

1,030,108

594,738

2,887,328

2,115,307

32,011

374,845

82,229

641,326

5,540

4,298

82,869

37,629

2,199,090

1,235,074

7,484,668

6,501,210

5,777,965

2,536,139

9,882,501

7,623,964

Summary of accounts payable and accrued liabilities [Abstract]

Accounts payable - suppliers

1,628,737

1,686,431

Accrued commissions

173,110

238,150

Accrued royalties / license fees

976,421

583,923

Accrued payroll

226,220

262,439

Accrued vacation

223,412

181,636

Accrued bonuses

422,225

155,663

Accrued expenses - other

284,911

195,681

TOTAL

$3,935,036

$3,303,923

COLLABORATIVE_RESEARCH_AND_DEV1

COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS (Details) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

Apr. 03, 2013

Jun. 30, 2009

Sep. 30, 2013

Sep. 30, 2012

Mar. 31, 2011

Sep. 30, 2013

Sep. 30, 2012

Jul. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Jul. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Development of Test for Leptospirosis [Member]

Development of Test for Tuberculosis [Member]

Development Of Test For Ferbile [Member]

(DPP?) Technology [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Grant received

$2,800,000

$2,900,000

Term of grant

'3 years

Revenue earned from grant

367,000

470,000

487,000

Revenue from grants from inception

2,800,000

2,153,000

470,000

594,000

Amount paid to subcontractors

897,000

651,000

Maximum amount of development agreement

953,000

753,000

480,000

Period in which development activity is to be completed

'8 months

'9 months

Research and development payments received under the agreement

$470,000

$316,000

$18,000

LOANS_PAYABLE_Details

LOANS PAYABLE (Details) (USD $)	9 Months Ended
LOANS PAYABLE (Details) (USD $)	Sep. 30, 2013
Demand Note [Member]	'
Line of Credit Facility [Line Items]	'
Maximum borrowing capacity	$2,000,000
Interest rate description	'one-quarter percent above prime per annum
Clean-up period	'30 days
Security Agreement [Member]	'
Debt Instrument [Line Items]	'
Debt covenants, description	'The Security Agreement, related to the Demand Note, contains covenants that place restrictions on the Companybs operations, including covenants relating to mergers, debt restrictions, capital expenditures, tangible net worth, net profit, leverage, fixed charge coverage, employee loan restrictions, distribution restrictions (common stock and preferred stock), dividend restrictions, restrictions on lease payments to affiliates, restrictions on changes in business, asset sale restrictions, restrictions on acquisitions and intercompany transactions, and restrictions on fundamental changes in the Company and in its business.

RIGHTS_AGREEMENT_Details

RIGHTS AGREEMENT (Details) (USD $)	0 Months Ended
RIGHTS AGREEMENT (Details) (USD $)	Mar. 08, 2010	Sep. 30, 2013	Dec. 31, 2012
RIGHTS AGREEMENT [Abstract]	'	'	'
Conversion basis of dividend distribution	'one preferred share purchase right (a "Right") for each outstanding share of Common Stock	'	'
Common stock, par value (in dollars per share)	$0.01	$0.01	$0.01
Minimum combined ownership of outstanding shares of common stock by acquiring person (in hundredths)	'	15.00%	'

COMMON_STOCK_WARRANTS_AND_OPTI1

COMMON STOCK, WARRANTS AND OPTIONS (Details) (USD $)	0 Months Ended	3 Months Ended			9 Months Ended
	22-May-13	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2013	Sep. 30, 2012	30-May-12
	22-May-13	Sep. 30, 2013	Installment	Installment	Sep. 30, 2013	Sep. 30, 2012	30-May-12
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Stock options issued to purchase of common stock (in shares)	5,000	'	5,000	30,000	30,000	'	'
Exercise price of stock option (in dollars per share)	'	'	$4.50	'	'	'	'
Expiration period of stock option	'	'5 years	'	'	'	'	'
Options expected to vest in each anniversary (in shares)	'	'	2,500	'	'	'	'
Number of equal annual installments with in which options are exercisable	'	'	2	3	'	'	'
Minimum period after termination of employment to exercise stock options by employees	'	'	'30 days	'30 days	'	'	'
Warrants outstanding (in shares)	'	0	'	'	0	'	'
Shares sold in underwritten public offering (in shares)	'	'	1,200,000	'	'	'	'
Price per share of common stock sold in the offering (in dollars per share)	'	'	'	'	'	'	$5
Proceeds from sale of offering	'	'	$5,401,000	'	$5,512,500	$0	'
Executives [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Stock options issued to purchase of common stock (in shares)	'	'	'	'	16,360	'	'
Exercise price of stock option (in dollars per share)	'	5.56	'	'	'	'	'
Expiration period of stock option	'	'5 years	'	'	'	'	'
Senior Vice President [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Exercise price of stock option (in dollars per share)	'	5.44	'	'	'	'	'
Options expected to vest in each anniversary (in shares)	'	10,000	'	'	10,000	'	'

COMMITMENTS_CONTINGENCIES_AND_2

COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

22-May-13

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

KeyEmployee

Economic Dependency [Abstract]

Sales

$9,044,714

$4,745,094

$20,419,595

$16,919,436

Accounts Receivable

5,505,215

4,821,357

Accounts Payable

1,628,737

1,686,431

Employment Agreement [Abstract]

Number of key employees with whom Company has employment contracts

Aggregate annual salaries of employment contracts

840,000

Stock options issued to purchase of common stock (in shares)

5,000

30,000

Vesting rights of awards

'one-half

'one-third

Customer4 [Member]

Economic Dependency [Abstract]

Sales

Customer Concentration Risk [Member]

Economic Dependency [Abstract]

Concentration risk percentage, minimum (in hundredths)

10.00%

Customer Concentration Risk [Member] | Customer 1 [Member]

Economic Dependency [Abstract]

Accounts Receivable

843,554

648,084

843,554

648,084

Customer Concentration Risk [Member] | Customer 2 [Member]

Economic Dependency [Abstract]

Accounts Receivable

715,310

1,326,098

715,310

1,326,098

Customer Concentration Risk [Member] | Customer 3 [Member]

Economic Dependency [Abstract]

Accounts Receivable

2,365,950

[1]

2,365,950

[1]

Customer Concentration Risk [Member] | Customer4 [Member]

Economic Dependency [Abstract]

Accounts Receivable

Supplier Concentration Risk [Member] | Vendor 1 [Member]

Economic Dependency [Abstract]

Accounts Payable

95,170

[2]

89,710

95,170

[2]

89,710

Supplier Concentration Risk [Member] | Vendor 2 [Member]

Economic Dependency [Abstract]

Accounts Payable

57,555

[2]

60,073

57,555

[2]

60,073

Sales [Member] | Customer Concentration Risk [Member] | Customer 1 [Member]

Economic Dependency [Abstract]

Sales

2,167,999

1,187,124

7,063,682

5,780,030

Concentration risk, percentage (in hundredths)

24.00%

25.00%

35.00%

34.00%

Sales [Member] | Customer Concentration Risk [Member] | Customer 2 [Member]

Economic Dependency [Abstract]

Sales

1,887,166

2,522,405

3,756,262

7,241,430

Concentration risk, percentage (in hundredths)

21.00%

53.00%

18.00%

44.00%

Sales [Member] | Customer Concentration Risk [Member] | Customer 3 [Member]

Economic Dependency [Abstract]

Sales

3,866,894

[1]

5,924,900

[1]

Concentration risk, percentage (in hundredths)

43.00%

[1]

29.00%

[1]

Sales [Member] | Customer Concentration Risk [Member] | Customer4 [Member]

Economic Dependency [Abstract]

Concentration risk, percentage (in hundredths)

Purchases [Member] | Supplier Concentration Risk [Member] | Vendor 1 [Member]

Economic Dependency [Abstract]

Concentration risk, percentage (in hundredths)

12.00%

[2]

15.00%

8.00%

[2]

14.00%

[2]

Purchases

299,648

[2]

204,607

675,765

[2]

613,287

[2]

Purchases [Member] | Supplier Concentration Risk [Member] | Vendor 2 [Member]

Economic Dependency [Abstract]

Concentration risk, percentage (in hundredths)

11.00%

[2]

16.00%

10.00%

[2]

13.00%

[2]

Purchases

$275,539

[2]

$211,020

$840,923

[2]

$589,224

[2]

[1]

Product sales did not exceed 10% for the period.

[2]

Purchases did not exceed 10% for the period indicated

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	3 Months Ended		6 Months Ended	9 Months Ended
INCOME TAXES (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2013	Sep. 30, 2013	Sep. 30, 2012
INCOME TAXES [Abstract]	'	'	'	'	'
Interim provision estimated effective tax rate (in hundredths)	35.10%	'	'	'	'
Threshold percentage of loss offset by NOLs (in hundredths)	90.00%	'	'	'	'
Income tax provision percentage from accrued expenses (in hundredths)	3.50%	'	'	10.00%	'
Amount added to accrued expenses	$39,800	'	'	'	'
Income tax provision	358,850	-193,310	398,000	398,940	295,220
Income tax provision percentage from reduction of the deferred tax asset (in hundredths)	31.60%	'	'	'	'
Provision for deferred taxes	$358,200	'	'	$359,046	$265,698